Lv53
1370 积分 2024-12-29 加入
Risankizumab for Ulcerative Colitis
56分钟前
已完结
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
58分钟前
待确认
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
1小时前
求助中
Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management?
1个月前
已完结
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
2个月前
已关闭
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study
2个月前
已完结
Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
3个月前
已完结
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis
3个月前
已完结
Tunneling nanotube–like structures regulate distant cellular interactions during heart formation
3个月前
已完结
Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: a systematic review and meta‑analysis of randomized controlled trials
3个月前
已完结
皖公网安备34019202002308
